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Abstract
Background: Pathological Golgi fragmentation represents a constant pre-clinical feature of many neurodegenerative
diseases including amyotrophic lateral sclerosis (ALS) but its molecular mechanisms remain hitherto unclear.
Results: Here, we show that the severe Golgi fragmentation in transgenic mutant SOD1G85R and SOD1G93A mouse
motor neurons is associated with defective polymerization of Golgi-derived microtubules, loss of the COPI coat
subunit β-COP, cytoplasmic dispersion of the Golgi tether GM130, strong accumulation of the ER-Golgi v-SNAREs GS15
and GS28 as well as tubular/vesicular Golgi fragmentation. Data mining, transcriptomic and protein analyses
demonstrate that both SOD1 mutants cause early presymptomatic and rapidly progressive up-regulation of the
microtubule-destabilizing proteins Stathmins 1 and 2. Remarkably, mutant SOD1-triggered Golgi fragmentation and
Golgi SNARE accumulation are recapitulated by Stathmin 1/2 overexpression but completely rescued by Stathmin
1/2 knockdown or the microtubule-stabilizing drug Taxol.
Conclusions: We conclude that Stathmin-triggered microtubule destabilization mediates Golgi fragmentation in
mutant SOD1-linked ALS and potentially also in related motor neuron diseases.
Background
Structural alterations of the Golgi apparatus are among
the earliest and most constant pathological features in
neurodegenerative diseases and have been widely studied
in the motor neuron disease amyotrophic lateral sclerosis
(ALS) [16, 23, 57]. The Golgi alterations are detectable in
degenerating ALS motor neurons of spinal cord and cere-
bral motor cortex [20, 36], are common to both sporadic
[22] and familial forms of the disease [21, 24, 31, 36, 58],
and manifest at presymptomatic stage [36, 65, 66].
The Golgi apparatus of normal motor neurons is made
of stacked membrane-bound cisternae that are laterally
connected to form the Golgi ribbon [5]. Earlier studies in
particular by Gonatas and colleagues have characterized
the structural Golgi alterations in ALS motor neurons as
fragmentation [22], i.e. transformation of the Golgi ribbon
into disconnected stacks or into tubules and vesicles [5],
and as atrophy [22, 36], i.e. loss or dispersion of Golgi
membranes. In the most widely studied ALS mouse
model, transgenic mutant SOD1G93A mice, Golgi frag-
mentation can affect up to 75 % of spinal cord motor neu-
rons at symptomatic stage [36, 65].
The Golgi apparatus is a highly dynamic cellular organ-
elle that ensures the processing and sorting of proteins
form their site of synthesis in the endoplasmic reticulum
(ER) en route to their final destination, which is reflected
by its functional division into a cis(entry) side and a
trans(exit) side. Intra-Golgi transport involves COPI-coated
vesicles [2] which are formed through recruitment of
coatomers α-ζ [43], tethered by Rabs and Golgins [37] and
fused/docked to target membranes by Golgi SNAREs [29].
While the molecular mechanisms of Golgi fragmenta-
tion in ALS remain largely to be deciphered, at least two
mechanisms can been proposed. The first mechanism
involves an impairment in transport from endoplasmic
reticulum (ER) to Golgi [4, 52] and from Golgi to plasma
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membrane [54]. Both could in turn affect Golgi structure.
The second mechanism involves potential microtubule al-
terations [36]. Microtubules are indeed closely associated
with the Golgi [30, 50] and nucleated at its membrane
[8, 14] in motor neurons [5]. Furthermore, pharmaco-
logical microtubule disruption with colchicine or nocoda-
zole causes reversible Golgi fragmentation and dispersal
[15, 47, 61]. Finally, we have recently demonstrated that
defective polymerization of Golgi-derived microtubules
causes Golgi fragmentation in motor neurons of pmn
mice with progressive motor neuronopathy which are mu-
tated in the tubulin-binding cofactor E (Tbce) gene [5].
The role of microtubules in mutant SOD1-linked Golgi
fragmentation remained however unclear. Indeed, micro-
tubules appeared normal in motor neuron cell bodies
with a fragmented Golgi [53] despite their early alter-
ations in axons [17, 70]. In addition, dys-regulation of a
microtubule-severing protein (Stathmin-1) was seen only
in a fraction of motor neurons with Golgi fragmentation
and only at late disease stage [55], suggesting that it may
represent a compensatory event.
To analyze the mechanisms of Golgi pathology in ALS,
we here investigated two transgenic mouse lines with simi-
lar disease course due to either dismutase active (G93A) or
inactive (G85R) human SOD1. Mutant SOD1G93A mice
(line G1del) develop limb weakness between day 165 to
240 and fatal paralysis about 40 days later [1]. Mutant
SOD1G85R mice (line 148) develop limb weakness between
day 240 to 280 and die about 15 days later [6]. As controls,
we used non-transgenic litter mice and mice expressing
wild type human SOD1 (SOD1wt, line 76) at a similar level
as in the mutants. In addition, we used NSC-34 cells trans-
fected with mutant or wildtype SOD1 as in vitro sys-
tem. We show that the early Golgi pathology observed
in mutant SOD1G85R and SOD1G93A motor neurons in-
volves disruption of the Golgi-nucleated somatic micro-
tubule network due to up-regulation of the two
microtubule-severing proteins Stathmin 1 and 2. This
in turn leads to Golgi fragmentation with early pre-
symptomatic and rapidly progressive accumulation of
the ER-Golgi v-SNAREs GS28 and GS15. These data,
together with our findings in ALS-like pmn mice [5],
lead us to propose that a disruption of Golgi-nucleated
microtubules underlies Golgi fragmentation in human
SOD1-linked ALS and related degenerative motor
neuron diseases.
Results
To confirm the reported Golgi alterations in mutant
SOD1 motor neurons [36, 65, 66], we first examined lum-
bar spinal cord cryosections from 240-day-old mice by
confocal microscopy using GM130 antibodies. We dem-
onstrate that Golgi membranes form a dense ribbon in
the cell bodies of control and SOD1wt motor neurons, but
appear fragmented or atrophied in motor neurons of
mutant SOD1G85R and SOD1G93A mice (Fig. 1a). Golgi
fragmentation was confirmed by GM130 membrane mod-
eling demonstrating an ~4 fold increase in the number of
individual Golgi profiles in SOD1G85R and SOD1G93A
motor neurons when compared to control (Fig. 1a,b). Loss
of Golgi area in SOD1G85R and SOD1G93A motor neurons
was quantified by a reduction in its cross-sectional area
to ~35 % of normal (Fig. 1a,c, Additional file 1: Figure S1A).
To confirm that Golgi fragmentation precedes disease
onset in ALS [36, 65, 66], we analyzed mutant SOD1G93A
mice and SOD1G85R mice, respectively one month before
(age 130 days) and two months before (age 180 days) the
onset of first clinical symptoms and before any reported
loss of motor neurons. Up to 19 % of mutant SOD1 motor
neurons displayed signs of Golgi fragmentation labelled by
GM130, as compared to < 1 % of motor neurons in non-
transgenic and SOD1wt mice (Fig. 1d and Additional file 1:
Figure S1B). This compares very well with published re-
sults at least in mutant SOD1G93A mice, where Golgi
fragmentation is scored in 25-30 % of motor neurons
about 10 days later at 20 weeks of age [65].
To confirm and characterize the changes of the Golgi
architecture, we analyzed presymptomatic mutant SOD1
mice aged 140 days at the ultrastructural level by electron
microscopy. In control mice (Fig. 1e, upper left panel) and
in transgenic SOD1wt mice (not shown), the Golgi appar-
atus exhibits the typical morphology of stacked cisternae
as described in [5]. Conversely, in motor neurons of mu-
tant SOD1 mice, we observe a fragmentation of the Golgi
ribbon into many disconnected Golgi stacks, small tubules
and vesicles that appear uncoated as well as unlinked
(Fig. 1e, arrows in lower left panels).
To analyze the molecular basis of the observed Golgi
fragmentation in mutant SOD1 motor neurons, we in-
vestigated the status of Golgi vesicle coats, tethers and
SNAREs using biochemical methods. We found that the
level of the COPI vesicle subunit β-COP is lower in
mutant SOD1G85R and SOD1G93A spinal cords than in
control spinal cords, whereas the level of the COPII vesicle
subunit Sec23 remains normal (Fig. 1f, upper panels).
The Golgi tethering protein GM130 is normally associ-
ated with the cytoplasmic face of cis-medial Golgi mem-
branes and binds the Golgi tether p115 present on
incoming vesicles [38]. We found that the total levels of
GM130 and p115 are unchanged in mutant SOD1 spinal
cords when compared to control (Fig. 1f, lower panels).
Since the membrane association of GM130 and p115 is
critical for their function [37], we investigated a potential
subcellular redistribution of both Golgi tethers in mutant
SOD1 mice by biochemical fractionation of spinal cords
into membrane (P10), vesicle (P100) and cytosol (S100)
fractions. We found that GM130 is significantly redistrib-
uted from its typical Golgi membrane localization in
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control mice to vesicles, membrane fragments and cytosol
in SOD1G85R and SOD1G93A mice (Fig. 1g, blots and
diagram). Interestingly, this subcellular redistribution is
specific for GM130 since p115 remains associated with
the vesicle fraction as in control mice (Fig. 1g). The purity
of the P10, P100 and S100 fractions was confirmed by
analysis of molecular markers L1, Vt1a and GAPDH
(Additional file 1: Figure S2). These data suggest that
mutant SOD1 expression leads to defective tethering of
Golgi vesicles due to redistribution of GM130.
Last, Golgi SNAREs mediate vesicle fusion through
interaction of v-SNAREs (present on vesicles) and
t-SNAREs (present on target membranes) [26, 29]. Using
immunofluorescence, we found that the ER-Golgi v-
SNAREs GS28 [56] and GS15 [71] are present in small
dispersed profiles in mutant SOD1G85R and SOD1G93A
motor neurons when compared to control motor
neurons (Fig. 1h). Furthermore, Western blots showed
that the total spinal cord levels of GS28 and GS15 are
increased by > 4 fold and >3 fold respectively in mutant
SOD1G85R mice and SOD1G93A mice when compared to
control mice (Fig. 1i, upper panels and diagrams). This
is specific for GS15 and 28 because, by contrast, the
levels of Syntaxin5a, the major Golgi t-SNARE cognate of
GS28 and GS15, and of the endosomal v-SNARE Vti1a,
are unchanged in mutant SOD1 mice (Fig. 1i, lower
panels). Importantly in SOD1wt spinal cords, the levels of
all tested SNARE proteins are identical to those in non-
transgenic mice (Fig. 1h, upper panels), indicating a
specific and significant increase of Golgi v-SNAREs
GS28 and GS15 in mutant SOD1 spinal cords.
In order to set up a tractable in vitro model, we repro-
duced these Golgi alterations in cultured NSC-34 motor
neurons [7] expressing mutant SOD1 (Fig. 2). Using
MannII-GFP or GM130 as Golgi markers, the Golgi
appears as a compact juxtanuclear structure in control cells
transfected with empty or SOD1wt plasmids but is fragmen-
ted in cells transfected with SOD1G85R or SOD1G93A
plasmids (Fig. 2a,b and Additional file 1: Figure S1C).
Expression of both SOD1 mutants also triggers dispersal of
GS28, as shown by IF (Fig. 2a,c) and a >2 fold increase in
protein levels of GS28 and GS15, as shown by Western blot
(Fig. 2d).
Taken together, these results show that both in spinal
motor neurons and in NSC-34 cells, expression of mutant
SOD1G85R and SOD1G93A causes loss of β-COP, re-
distribution of GM130 and strong accumulation of Golgi
SNAREs GS28 and GS15, in line with the observed Golgi
fragmentation. Importantly, these alterations closely resem-
ble those that we previously observed in pmn mice [5].
Mutant SOD1 proteins localize to the Golgi and impede
the polymerization of Golgi-derived microtubules
Given that the molecular features observed in pmn mice
are triggered by a point mutation in Golgi-localized TBCE
that affects the Golgi microtubule network, we won-
dered whether mutant SOD1 also impairs Golgi-derived
microtubules.
(See figure on previous page.)
Fig. 1 Morphological and molecular Golgi alterations in motor neurons of mutant SOD1 mice. a. Confocal z-stacks (upper panels) show fragmentation of
GM130-labeled Golgi membranes in lumbar motor neurons of 240-day-old mutant SOD1G85R and SOD1G93A mice as compared to non-transgenic mice
and transgenic SOD1wt mice. Motor neurons are identified by expression of VaChT (vesicular acetylcholine transporter). 3D-modeling (lower panels) of
GM130-labelled Golgi membranes in entire motor neurons confirms Golgi fragmentation. Scale bars 10 μm. b. Increased number of GM130-stained Golgi
elements in mutant SOD1G85R and SOD1G93A motor neurons determined by 3D modeling of Golgi membranes in entire cells (mean ± sd, n = 12 motor
neurons from three mice per genotype, *** p < 0.0001 by student’s t-test, unpaired. c. Decreased cross-sectional area of GM130-labeled Golgi
area in mutant SOD1G85R and SOD1G93A motor neurons as compared to control motor neurons (mean ± sd, *** p < 0.001, n = 50 motor neurons from
three mice per genotype, student's t test). See also Additional file 1: Figure S1. d. Percentage of motor neurons with GM130-labeled Golgi fragmentation
at presymptomatic stage (mean ± sd, *** p < 0.001 by student’s t-test, n > 250 motor neurons from four mice per genotype were analyzed at
presymptomatic stage corresponding to age 130 days (SOD1G93A, non Tg) or 180 days (SOD1G85R, SOD1wt). e. Electron microscopy of a lumbar
motor neuron from a non-transgenic mouse aged 140 days showing a typical Golgi apparatus (upper panel) that is easily distinguished from
unlinked, partially swollen and vesiculated Golgi profiles observed in mutant SOD1G93A motor neurons (arrows in lower panel, magnifications
on the right). n: nucleus, m: mitochondria. Scale bars 500 nm (left panels), 200 nm (right panels). f. Western blots showing decreased levels of
β-COP in mutant SOD1 mice, and normal levels of Sec23, GM130 and p115. Loading control β-actin. Shown is one representative blot per genotype out of
four. The diagram below shows that β-COP levels (normalized to β-actin) are reduced to 25 ± 7.7 % and 42.5 ± 9.6 % of non Tg (mean ± sd, n = 4 per
genotype, * p < 0.01 by Mann Whitney test). g. Subcellular fractionation of spinal cords. Western blot analyses show redistribution of GM130 in mutant
SOD1 mice, as indicated by shift from its normal membrane localization in control and SODwt mice into fragmented membranes and vesicles in SOD1G85R
and SOD1G93A mice and cytosol. P115 is not redistributed. Each blot is representative of three independant experiments on mice of the indicated
genotypes. The diagram below shows densitometric determination of protein distribution (mean ± sd, n = 3 per genotype, * p < 0.01 by Mann Whitney
test). h. Confocal imaging reveals accumulation of Golgi v-SNARE protein GS28 (upper panels) and GS15 (lower panels) in small vesicle-like punctae of
motor neurons in mutant SOD1 mice, as compared to controls. Scale bars 10 μm. i. Western blots (upper two panels) demonstrating massively
increased levels of Golgi v-SNAREs GS28 and GS15 in mutant SOD1G85R and SOD1G93A lumbar spinal cords, as compared to non-transgenic
and SOD1wt spinal cords. Western blots (lower three panels) showing normal expression of the Golgi t-SNARE Syntaxin-5a and the endosomal
v-SNARE Vti1a. β-actin indicates equal protein loading. Each blot is representative of three independant experiments on mice of the
indicated genotypes. The diagrams show increased spinal cord protein levels of GS28 by 4 ± 1.6 (SOD1G85R) and by 3.7 ± 1.3 (SOD1G93A) fold and of
GS15 by 3.7 ± 0.7 (SOD1G85R) and by 3.2 ± 1 (SOD1G93A) as compared to non Tg control (mean ± sd, * p < 0.001 by Mann Whitney test)
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Previous studies in non-motor neuronal cells have
localized a significant fraction of SOD1 to Golgi mem-
branes [63, 64]. To confirm this, we transfected RFP-
tagged forms of wildtype and mutant SOD1 together
with MannII-GFP in NSC-34 cells. After extraction of
soluble proteins, co-localization and Pearson correlation
analysis showed that both RFP-tagged SOD1wt, SOD1G85R
and SOD1G93A indeed significantly co-localize with
MannII-GFP-labeled Golgi membranes whereas RFP is
mainly nuclear (Fig. 3a, upper three panels).
Since the Golgi membrane is a major site of micro-
tubule polymerization and nucleation in motor neurons
Fig. 2 Golgi alterations in mutant SOD1-transfected NSC-34 motor neurons. a. Confocal images (upper panels) showing Golgi fragmentation with
the marker MannII-GFP in NSC-34 cells transfected for 4 DIV with mutant SOD1, as compared to the situation in control or wildtype SOD1-transfected
cells. Confocal images (lower panels) showing GS28 dispersal after transfection with mutant SOD1, as compared to the situation in control or wildtype
SOD1 cells. Scale bar 10 μm. b. Percentage of cells (mean ± sd) with Golgi fragmentation labeled for MannII-GFP. More than 300 cells per condition
were analyzed on quadruplicate wells per condition. Statistical significance * p < 0.01 by Mann–Whitney test, as compared to mock and SODwt. Data
represent one out of three experiments yielding similar results. c. Percentage of transfected cells with dispersal of GS28. More than 200 cells
per condition were analyzed on quadruplicate wells per condition. Statistical significance * p < 0.01 by Mann–Whitney test, as compared to
mock and SODwt. d. Western blot analysis of NSC-34 cells demonstrating that GS28 protein levels are increased to 2.7 ± 0.7 and 2.9 ± 0.8
by SOD1G85R and SOD1G93A, respectively, as compared to those in control SODwt. GS15 protein levels are increased to 2.7 ± 0.2 and 3.0 ±
0.3 fold, respectively. The diagrams show densitometric quantification of protein levels relative to SODwt (mean ± sd). Cellular extracts
from three independently transfected cultures were blotted and analyzed each in duplicate. Statistical significance * p < 0.01 by Mann
Whitney test
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[5, 8, 14], we then tested whether SOD1 mutants affect
the polymerization of microtubules. By IF, microtubules
appear disorganized and rarefied around MannII-GFP-la-
beled Golgi punctae in mutant SOD1 cells when compared
to control cells (Fig. 3a, lower panel). To confirm this, we
biochemically analyzed detyrosinated tubulins, which are
markers of Golgi-associated microtubules [50, 60], by deter-
mining their total, soluble and polymerized fractions
(Fig. 3b). The ratio of polymerized versus total detyrosinated
tubulin is significantly lower in mutant SOD1G85R cells and
SOD1G93A cells than in SOD1wt cells (Fig. 3b, upper panels).
The ratio of polymerized versus total α-tubulin in mutant
SOD1 cells is also decreased, albeit to a lower extent (Fig. 3b,
middle panels). These data indicate that both SOD1 mutants
impede the polymerization of Golgi-derived microtubules.
To determine the microtubule content in individual cells,
we extracted soluble tubulins, labeled polymerized micro-
tubules with FITC-coupled antibodies against α-tubulin
and performed flow cytometry. This method accurately
measures cellular microtubules since the flow cytome-
try signals of cells are increased after treatment with
the microtubule-stabilizing drug Taxol, decreased after
treatement with the microtubule-disrupting drug Noco-
dazole and correlated with the amount of biochemically
fractionated microtubules (Additional file 1: Figure
S3A-B). Using this technique, we found significantly
less polymerized microtubules in cells expressing RFP-
tagged SOD1G85R or SOD1G93A than in cells expressing
RFP-SOD1wt or RFP (Fig. 3c), confirming the mutant
SOD1-triggered loss of cellular microtubules.
To directly measure the polymerization rate of microtu-
bules at the Golgi, we incubated control and mutant
SOD1 NSC-34 cells with Nocodazole, restored the cells
to drug-free medium and measured the regrowth of
Golgi-derived microtubules over 12 min using α-
tubulin/MannII-GFP labeling (Fig. 3d). In control cells ex-
pressing RFP or RFP-SOD1wt, small microtubule asters
form at Golgi profiles within few minutes after nocoda-
zole washout. These microtubules then grow rapidly, con-
firming the capacity of Golgi membranes to nucleate
microtubules [5, 8, 14]. In mutant SOD1 expressing cells,
however, Golgi-derived microtubule asters are rare and
grow slowly. Their mean growth rate is reduced by over
50 % in SOD1G85R and SOD1G93A cells in comparison
to RFP expressing cells (Fig. 3e). Wildtype SOD1 does
not impede growth of Golgi-derived microtubules
(Fig. 3e). Taken together, these data indicate that SOD1
mutants decrease the growth rate and steady state
levels of Golgi-derived microtubules.
Last, to test whether these microtubule defects are re-
sponsible for the observed Golgi alterations, we stabilized
microtubules in mutant SOD1- and control-transfected
cells by treating the cultures with Taxol (10 nM) from 0 to
4 DIV. We found that Taxol significantly reduces the
percentage of mutant SOD1-transfected cells harboring
MannII-GFP-labeled Golgi alterations (Fig. 3f), indicating
that microtubule defects mediate the mutant SOD1-
triggered Golgi alterations.
Mutant SOD1 causes up-regulation of Stathmin 1 and 2
gene expression
To identify the upstream triggers of microtubule loss and
tubular/vesicular Golgi fragmentation in mutant SOD1
motor neurons, we performed data mining and bioinfor-
matic analyses. We first analyzed five studies comparing
the gene expression profiles of SOD1G93A and control
(See figure on previous page.)
Fig. 3 SOD1 mutants impair polymerization of Golgi-derived microtubules. a. Images show NSC-34 cells expressing RFP or SOD1 variants tagged
with RFP after extraction for soluble proteins and labeling with MannII-GFP (Golgi) and antibodies against α-tubulin (microtubules). Merged RFP/
MannII-GFP images show that both wildtype SOD1 (arrow) and mutant SOD1 (arrowheads) localize to Golgi membranes. This is confirmed by
Pearson’s correlation analysis (RFP-SOD1wt 0.74 ± 0.09, RFP-SOD1G85R 0.72 ± 0.09, RFP-SOD1G93A 0.77 ± 0.14, RFP 0.13 ± 0.14, statistical significance
SOD1 variants vs RFP : p < 0.0006 by student’s t-test). Mutant SOD1G85R and SOD1G93A specifically cause rarefaction of microtubules around frag-
mented Golgi profiles (arrowheads in lower panel). b. Biochemical fractionation of total (T), soluble (S) and polymerized (P) tubulins. Cells express-
ing SOD1G85R or SOD1G93A display a decreased ratio of polymerized detyrosinated (detyr-) tubulin. The ratio of polymerized α-tubulin is also
decreased. Polymerization of β-actin is not affected by mutant SOD1. % P is equivalent to P/(P + S), * p < 0.01 by Mann–Whitney test, n = 3 experi-
ments each. c. Flow cytometry of cellular microtubules in NSC-34 cells after extraction of soluble tubulins, microtubule stabilization and intracellu-
lar labeling with α-tubulin-FITC antibodies. Cells expressing SODwt (in grey, upper panel) display normal levels of α-tubulin-containing
microtubules in comparison to cells expressing RFP (in black). Cells expressing mutant SOD1G85R (in green, middle panel) or mutant SOD1G93A (in
blue, lower panel) show decreased levels of cellular microtubules. Median fluorescence signal per cell: 15.800 (RFP), 15.900 (SOD1wt), 11.600
(SOD1G85R), 8.418 (SOD1G93A). Statistical significance by chi square test, * T(x) > 200, ns T(x) = 0. d. Images showing transfected NSC-34 cells that
were treated with Nocodazole (left column) and restored to drug-free medium for 12 min (right four columns). Cells were identified by RFP ex-
pression (not shown), Golgi profiles were identified by MannII-GFP and growing microtubules with antibodies against α-tubulin (pseudocolored
in red). Mutant SOD1G85R and SOD1G93A impede regrowth of Golgi-derived microtubules (zoomed insets). Scale bar 5 μm. e. Diagrams showing
reduced growth rate of Golgi-derived microtubules in cells expressing RFP- SOD1G85R (upper panel) or RFP- SOD1G93A (lower panel) as compared
to cells expressing RFP- SOD1wt or RFP. Microtubule length represents mean of mean of >12 cells per time point and condition and a total of
1495 microtubules analyzed. Statistical significance **** p < 0.0001 (RFP-SOD1G85R vs RFP or vs SOD1wt) and **** p < 0.0001 (RFP-SOD1G93A vs RFP
or vs SOD1wt) by ANOVA test and Tukey’s multiple comparison test. f. Diagrams showing Taxol-mediated rescue of MannII-GFP-labeled Golgi frag-
mentation in cells expressing mutant SOD1G85R or SOD1G93A each tagged to RFP. Statistical significance * p < 0.01 (Taxol vs mock) by Mann–Whit-
ney test, n ≥ 50 cells per well and 4 replicate wells were analyzed per condition
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motor neurons isolated by laser capture microdissection
from adult spinal cord [19, 28, 33, 40, 42]. Two studies
showed that cytoskeleton-related genes annotated to
the Gene Ontology (GO) terms “cytoskeletal part/
GO:0044430” and “cytoskeleton/GO:0005856” are sig-
nificantly dys-regulated: 14 genes at presymptomatic
stage [33]), 76 genes at early disease stage [33]) and 42
genes at end stage [42]). Among those, genes annotated
to the microtubule cytoskeleton (GO:0015630) display
significant dys-regulation [33].
To identify individual dys-regulated genes linked to
microtubules, we then compared by bioinformatics ana-
lysis the publically available gene expression profiles
from mutant SOD1 G93A and control motor neurons
deposited in the Gene Omnibus database by Ferraiuolo
et al. as GSE10953 [19] and by Nardo et al. as GSE46298
[40]. Given the similarities between pmn and SOD1, we
first focused on tubulin binding co-factors but found
that the six genes Tbca, Tbcb, Tbcc, Tbcd, Tbce and
Tbcel (Tbce-like) are not significantly dys-regulated in
mutant SOD1 motor neurons at any time point (fold
change < 1.5, p > 0.05, Table 1).
By contrast, we found three Stathmin genes whose ex-
pression was significantly modulated in presymptomatic
mutant SOD1G93A motor neurons when compared to con-
trol. Stathmin 1 and Stathmin 2 were up-regulated by 1.87
and 1.63 fold respectively, whereas Stathmin 3 was down-
regulated by 1.71 fold at P60 (p < 0.05, Table 2). Stathmin 1
up-regulation (by 1.68 fold) also tended to occur at
end stage in an independent dataset of Perrin et al. [42],
although not reaching statistical significance (p = 0.06,
Table 2).
Table 1 Gene expression profiles of tubulin-binding cofactors in mutant SOD1 motor neurons
Ferraiuolo et al. 2007 Presymptomatic G93A vs. Ctrl (P60) Symptomatic G93A vs. Ctrl (P90) Endstage G93A vs. Ctrl (P120)
Gene Symbol Regulation Fold-Change P-Value Regulation Fold-Change P-Value Regulation Fold-Change P-Value
Tbca up 1,74 1,61 E-01 up 1,13 6,11E-01 down 1,63 9,62E-02
Tbcb up 1,03 9,24E-01 down 1,08 7,49E-01 down 1,33 6,17E-02
Tbcc down 1,09 8,24E-01 down 1,25 4,57E-01 up 1,03 9,71E-01
Tbcd down 1,14 8,10E-01 up 1,07 7,65E-01 down 1,03 9,32E-01
Tbce up 1,29 6,22E-01 up 1,01 9,87E-01 down 1,07 9,18E-01
Tbcel down 1,07 9,21 E-01 down 1,12 7,91 E-01 up 1,10 8,09E-01
Nardo et al. 2013 Presymptomatic C57 G93A vs. Ctrl Onset C57 G93A vs. Ctrl Symptomatic C57 G93A vs. Ctrl
Gene Regulation Fold-Change P-Value Regulation Fold-Change P-Value Regulation Fold-Change P-Value
Tbca up 1,23 1,81 E-01 down 1,03 8,53E-01 up 1,04 3,83E-01
Tbcb up 1,06 7,17E-01 down 1,15 5,21 E-01 down 1,04 8,46E-01
Tbcc up 1,16 2,81 E-01 down 1,10 2,12E-01 up 1,07 6,83E-01
Tbcd up 1,09 6,15E-01 up 1,01 9,47E-01 up 1,10 5,20E-01
Tbce up 1,11 6,02E-01 up 1,17 2,70E-01 up 1,10 1,05E-02
Tbcel up 1,06 6,01 E-01 up 1,10 4,47E-01 down 1,09 6,51E-01
Nardo et al. 2013 Presymptomatic 129sv G93A vs. Ctrl Onset 129sv G93A vs. Ctrl Symptomatic 129sv G93A vs. Ctrl
Gene Regulation Fold-Change P-Value Regulation Fold-Change P-Value Regulation Fold-Change P-Value
Tbca up 1,11 5,19E-01 down 1,11 2,51 E-01 down 1,10 4,67E-01
Tbcb up 1,22 2,89E-01 down 1,45 3,00E-03 down 1,45 1,61E-02
Tbcc up 1,20 1,50E-01 down 1,23 4,28E-02 down 1,06 3,85E-01
Tbcd up 1,28 1,37E-01 down 1,11 4,26E-01 down 1,06 5,97E-01
Tbce up 1,17 2,44E-01 down 1,20 8,76E-03 down 1,05 5,69E-01
Tbcel up 1,10 6,18E-01 up 1,01 9,11E-01 down 1,02 8,61E-01
Gene expression profiles from mutant SOD1 G93A and control motor neurons isolated by laser capture microdissection at different stage of disease [19, 40]
respectively were downloaded from the Gene Omnibus database and analyzed with EASANA software based on FAST DB annotations [12, 13]. Gene dysregulation
was considered significant at fold changes >1.5 and p-values < 5E-02
Genes encoding tubulin-binding cofactors Tbca to Tbcel are not significantly dys-regulated in mutant SOD1 motor neurons at any time point in the datasets
GSE10953 [19] or GSE46298 [40]
Note that mutant SOD1 G93A mice with genetic backgrounds C57BL/6 or 129sv and corresponding control mice were analyzed in the study of Nardo and
colleagues [40]. Here, onset of disease was defined when mice showed first signs of paw grip strength impairment and when body weight started to decline.
Symptomatic disease was defined when mice displayed a decrease of 50 % in their latency on grip strength and when body weight declined by >5 %
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Stathmins represent a family of four proteins (Stathmins
1 to 4), which destabilize microtubules either by seques-
tering tubulin dimers or by increasing the frequency of
microtubule catastrophes, i.e. their transition from steady
growth to rapid depolymerization [3, 10]. All Stathmins
are highly expressed in neurons, several of them localize
to the Golgi [10] and Stathmin 1 protein levels were found
increased in spinal cords of paralyzed (late stage)
SOD1G93A mice [55]. We therefore considered Stathmins
as good candidates for mutant SOD1-linked micro-
tubule alterations and Golgi fragmentation.
We analyzed whether one of the four Stathmins is dys-
regulated at the protein level in the spinal cord of mutant
SOD1 mice. Using Western blot, we found that levels of
Stathmin 1 (19 kD) and Stathmin 2 (also called SCG10,
~22 kD) are both increased by more than 3 fold in mutant
SOD1G85R and SOD1G93A spinal cords at age 240 days
(Fig. 4a) whereas they are not in SOD1wt mice (not shown).
Of note, this up-regulation is not observed for Stathmin 3
(RB3, ~26 kD) (not shown) and Stathmin 4 (RB3’, ~24 kD)
is undetectable. We therefore validate that expression of
mutant SOD1 triggers up-regulation of Stathmins 1 and 2
in motor neurons and conclude that this could cause the
observed microtubule defects and Golgi fragmentation.
Early and progressive co-accumulation of Stathmins and
GS28 in mutant SOD1 motor neurons
We then set out to test whether Stathmin up-regulation
could be causative of the Golgi fragmentation. As a first pre-
requisite to this, Stathmin up-regulation should have kinetics
matching the early onset and progression of Golgi pathology
in mutant SOD1 spinal cord [36, 65, 66]. To establish this,
we monitored the kinetics of Stathmin 1 and Stathmin 2
protein levels from early pre-symptomatic stage (postnatal
days P8 and P30) to disease endstage (P240) and compared
it to GS28 increase as a molecular sign of Golgi pathology.
The levels of Stathmin 1 and 2 in spinal cords of mutant
SOD1G85R and SOD1G93A mice are already significantly
Table 2 Gene expression profiles of Stathmins in mutant SOD1 motor neurons
Ferraiuolo et al. 2007 Presymptomatic G93A vs. Ctrl (P60) Symptomatic G93A vs. Ctrl (P90) Endstage G93A vs. Ctrl (P120)
Gene Regulation Fold-Change P-Value Regulation Fold-Change P-Value Regulation Fold-Change P-Value
Stmnl up 1,87 3,80E-02 up 1,21 4,54E-01 down 1,40 3,32E-01
Stmn2 down 1,03 9,47E-01 down 1,39 2,65E-01 up 1,91 3,96E-01
Stmn3 down 1,71 9,50E-03 down 1,44 2,73E-01 down 1,21 2,92E-01
Stmn4 down 1,02 9,61 E-01 up 1,39 5,15E-01 up 1,09 8,50E-01
Nardo et al. 2013 Presymptomatic C57 G93A vs. Ctrl Onset C57 G93A vs. Ctrl Symptomatic C57 G93A vs. Ctrl
Gene Regulation Fold-Change P-Value Regulation Fold-Change P-Value Regulation Fold-Change P-Value
Stmnl down 1,35 9,31 E-02 up 1,17 1,49E-01 up 1,16 3,48E-01
Stmn2 down 1,05 8.98E-01 down 1,52 2,38E-01 up 1,36 4,89E-01
Stmn3 up 1,07 7.28E-01 down 1,24 1,41 E-02 down 1,14 1,50E-02
Stmn4 down 1,06 6,69E-01 up 1,43 1,63E-01 up 1,36 3,15E-02
Nardo et al. 2013 Presymptomatic 129v G93A vs. Ctr Onset 129sv G93A vs. Ctrl Symptomatic 129sv G93A vs. Ctrl
Gene Regulation Fold-Change P-Value Regulation Fold-Change P-Value Regulation Fold-Change P-Value
Stmnl up 1,05 5,50E-01 up 1,06 3,40E-01 down 1,04 7,57E-01
Stmn2 up 1,63 1.98E-02 down 1,46 1,76E-01 down 1,71 9,08E-02
Stmn3 up 1,08 6,24E-01 down 1,25 6,38E-03 down 1,30 1,18E-02
Stmn4 down 1,13 3,75E-01 up 1,15 3,11E-01 up 1,23 2,98E-03
Perrin et al. 2006 Presymptomatic G93A vs. Ctrl (P60) Symptomatic G93A vs. Ctrl (P90) Endstage G93A vs. Ctrl (P120)
Gene Regulation Fold-Change P-Value Regulation Fold-Change P-Value Regulation Fold-Change P-Value
Stmnl down 1,38 nc down 1,38 nc up 1,68 6,00E-02
Stmn2 up 1,20 nc up 1,30 1,36E-01 up 1,12 6,44E-01
Stmn3 down 1,03 nc up 1,07 5,63E-01 down 1,02 8,36E-01
Stmn4 up 1,75 nc up 1,30 6,49E-01 up 1,85 nc
Gene expression profiles from mutant SOD1 and control motor neurons were analyzed with EASANA software based on FAST DB® annotations, see Table 1. Gene
dysregulation was considered significant at fold changes >1.5 and p-values < 5E-02. nc: non calculated
The Stmn1 and Stmn2 genes are significantly up-regulated at presymptomatic disease stage in datasets GSE10953 [19] and GSE46298/129sv [40] respectively, whereas
the Stmn3 gene is significantly down-regulated in dataset GSE10953 [19]. Stathmin-1 also tended to be up-regulated in the dataset kindly provided by F. Perrin [42]
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increased at P8 when compared to non-transgenic litter
mice (Fig. 4a-b). Their levels continue to rise at P30 and
P180 when compared to non-transgenic mice to finally
reach >3 fold normal levels at P240 (Fig. 4a-b).
Remarkably, this completely parallels the increase in
GS28 protein level with a 1.5 fold increase at P8 and a 4
to 6 fold increase at P240 (Fig. 4a-b). The accumulation
of Stathmins 1/2 and GS28 thus precedes by at least five
months the first clinical symptoms in two different lines
of mutant SOD1 mice. These data confirm that Golgi
pathology is an early preclinical sign in mutant SOD1
mice and show that the microtubule-disrupting proteins
Stathmin 1 and 2 are progressively up-regulated at kinet-
ics compatible with Golgi fragmentation.
As a second prerequisite, Stathmin up-regulation should
specifically occur in motor neurons displaying Golgi
SNARE accumulation. To test this, we identified individual
motor neurons by choline acetyl transferase (ChAT) ex-
pression (Additional file 1: Figure S4A-B) and examined
the levels of Stathmins and GS28 by IF on a cell-to-cell
basis (Fig. 4c-d). In normal motor neurons, Stathmin 1 is
barely detectable, Stathmin 2 is expressed in a faint punc-
tate fashion (Fig. 4c-d, upper left panels) and GS28 levels
are also low. In contrast, the increase in Stathmin 1 or 2
labeling intensities seen in numerous motor neurons of
mutant SOD1 mice (Fig. 4c-d, upper middle and right
panels, arrows) is matched by an increase in GS28 (Fig. 4c-
d, lower middle and right panels, arrows, Additional file 1:
Figure S4A-B). Interestingly, no up-regulation of GS28 or
Stathmins 1/2 was apparent in neighboring ChAT-negative
interneurons (Additional file 1: Figure S4A-B).
We also used regression analysis to demonstrate a clear
correlation between the immunoreactivities of Stathmin 1
and GS28 (Fig. 4e) and between Stathmin 2 and GS28
(Fig. 4f) in individual mutant SOD1 motor neurons.
As a third prerequisite, Stathmin 1 and 2 should be
expressed where microtubules are nucleated or polymer-
ized. In line with earlier reports [9], we find that Stathmin
2 is localized to the MannII-GFP-labelled Golgi in NSC-34
motor neurons whereas Stathmin 1 is mostly cytosolic
(Additional file 1: Figure S5).
In summary, the kinetics of Stathmin 1/2 up-regulation
and its close temporal and spatial correlation with GS28 ac-
cumulation in mutant SOD1 motor neurons all suggest that
Stathmin up-regulation may mediate Golgi fragmentation.
Overexpression of Stathmins 1/2 phenocopies expression
of mutant SOD1
If Stathmin 1/2 up-regulation is responsible for the Golgi
fragmentation observed in mutant SOD1 motor neurons
through its effect on the microtubule network, it should lead
on its own to the structural and molecular alterations de-
scribed above, i.e. microtubule disruption, Golgi fragmenta-
tion and Golgi SNARE accumulation. We first confirmed
that Stathmin 1/2 overexpression in NSC-34 motor neurons
leads to the expected microtubule defects. Indeed, we found
that the percentage of Stathmin 1 or 2 overexpressing NSC-
34 cells with altered microtubules is 3 fold higher than in
control-transfected cells (Fig. 5a-b). This is true for microtu-
bules containing α-tubulin or detyrosinated tubulin and simi-
lar to that in mutant SOD1-transfected cells (Fig. 3a,b,c,f).
We then tested whether Stathmin 1/2 overexpression
in NSC-34 cells triggers Golgi fragmentation and the as-
sociated accumulation of Golgi SNAREs GS28 and GS15
(Fig. 1g-i and Fig. 4). We found that it is the case. About
60 % of Stathmin 1 transfected cells exhibit a fragmented
Golgi and GS28 dispersal (Fig. 5c-d) and the protein
levels of GS28 and GS15 are >2.5 fold higher than in
control cells (Fig. 5e). Stathmin 2 transfected cultures
show a similar percentage of cells with Golgi fragmenta-
tion (Fig. 5c-d) and a similar increase in GS28/GS15
protein levels (Fig. 5e). Taken together, these data show
that Stathmin 1 and Stathmin 2 overexpression on its
own triggers both microtubule and Golgi alterations that
qualitatively and quantitatively resemble those observed
in mutant SOD1 motor neurons.
(See figure on previous page.)
Fig. 4 Early and rapidly progressive co-accumulation of Stathmin 1, Stathmin 2 and GS28 in motor neurons of mutant SOD1 mice. a. Western blots
show expression of Stathmin 1, Stathmin 2 and GS28 in lumbar spinal cords of SOD1G85R mice (upper panels), SOD1G93A mice (lower panels)
and corresponding litter mates. Analyses were performed at ages P8, P30, P180 and P240. Loading control β-actin. Each blot was performed in
duplicate and is representative of four animals per genotype. b. Diagrams showing kinetics of Stathmin 1, Stathmin 2 and GS28 protein levels
in lumbar spinal cords of mutant SOD1G85R mice and SOD1G93A mice. Stathmin 1 and 2 levels are already significantly increased at P8. Fold changes
(mean ± sd) are determined from four spinal cords per genotype and time point and expressed relative to the levels in non-transgenic littermate
controls (set to 1). Differences between mutant SOD1 and control are statistically significant as measured by Mann Whitney test (*, p < 0.01). c-d.
Confocal images of lumbar spinal cord cross sections from non-transgenic, SOD1G85R and SOD1G93A mice aged 240 days showing accumulation of
Stathmin 1 (C, upper panels), Stathmin 2 (D, upper panels) and GS28 (C-D, lower panels) in motor neurons, which sometimes appear as degenerating.
Note motor neurons with either low expression (arrowheads) or high expression (arrows) of Stathmins and Golgi SNAREs. Scale bar 20 μm. e. Diagram
showing immunoreactivities (IR) of Stathmin 1 (x-axis) and GS28 (y-axis) in motor neurons of control non-transgenic mice (in blue) and mutant
SOD1G85R mice (in red). Pearson analysis demonstrates significant correlation between both parameters: r = 0.28, p < 0.0066 (ctrl) and r = 0.47,
p < 0.0001 (SOD1G85R). The slopes of the regression curves are 0.49 ± 0.18 (ctrl) and 0.68 ± 0.13 (SOD1G85R), n = 91 cells (ctrl) and n = 99 cells
(SOD1G85R) analyzed from n = 3 mice per genotype. f. Immunoreactivities of Stathmin 2 and GS28 also show significant correlation by Pearson
analysis: r = 0.40, p < 0.0047 (ctrl), r = 0.69, p < 0.0001 (SOD1G85R). The slopes of the regression curves are 0.29 ± 0.09 (ctrl) and 0.60 ± 0.09
(SOD1G85R) by linear regression analysis, n = 47 cells and n = 48 cells analyzed respectively from n = 3 mice per genotype
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Knockdown of Stathmins 1 or 2 rescues mutant SOD1-linked
Golgi fragmentation
To conclusively validate the role of Stathmin 1/2 up-
regulation in mutant SOD1-triggered Golgi fragmentation,
we reasoned that removing Stathmins in mutant SOD1-
expressing NSC-34 cells should prevent microtubule loss
and Golgi fragmentation.
We found that RNAi-mediated knockdown of either
Stathmin 1 or Stathmin 2 reduces the percentage of cells
with mutant SOD1-triggered microtubule alterations
such as rarefied or discontinous microtubules to control
values (Fig. 6a-b). We further show that the knockdown
of either Stathmin 1 or 2 rescues the morphological
Golgi fragmentation evidenced by MannII-GFP (Fig. 6c)
and also the vesicular dispersion of GS28-labeled Golgi
profiles (Fig. 6c). Quantitative analyses (Fig. 6d-e) demon-
strate a complete rescue of both types of alterations.
Finally, we demonstrate that Stathmin 1 knockdown
normalizes the pathologically increased levels of GS28
triggered by SOD1G85R or SOD1G93A to those in SOD1wt
cultures (Fig. 6f ). Stathmin 2 knockdown has a similar
effect (Fig. 6g). Taken together, these data indicate that
Stathmins 1/2 mediate Golgi alterations in mutant SOD1
motor neurons by triggering microtubule loss.
Discussion
Our study shows that the early Golgi pathology observed
in mutant SOD1 motor neurons is triggered by the up-
regulation of Stathmins 1/2 that sever the Golgi-nucleated
microtubule network. This in turn leads to Golgi fragmen-
tation with tubular/vesicular organelle transformation as
its most prominent ultrastructural feature and strong ac-
cumulation of Golgi SNAREs GS28 and GS15 as its most
striking molecular signature.
Mutant SOD1-linked Golgi fragmentation is due to “somatic
microtubulinopathy”
Surprisingly, we find that Golgi fragmentation in mutant
SOD1 motor neurons in vivo and in vitro resembles that
described in pmn mice mutated in the Golgi-localized
tubulin folding chaperone TBCE, leading to TBCE deg-
radation and defective polymerization of Golgi-derived
microtubules in the cell soma [5]. This was unexpected
since microtubule alterations in mutant SOD1-linked
ALS have so far been only reported in axons, as illus-
trated by a reduction in axonal tubulin transport [70], an
accumulation of βIII-tubulin in axonal swellings [70] and
increases in hyperdynamic microtubules [17] or density
of EB3 comets [27] in axons. By contrast, our findings
show that mutant SOD1 impedes microtubule dynamics
at the Golgi in the motor neuron soma, leading in turn
to Golgi fragmentation. Of note, some forms of human
ALS are associated with mutations in the α-tubulin gene
TUBA4A and these severely disrupt the somatic micro-
tubule network upon overexpression [51]. We therefore
propose “somatic microtubulinopathy“ as a common mech-
anism triggering Golgi fragmentation in SOD1-linked ALS,
progressive motor neuronopathy, human TUBA4A-linked
ALS, and similar disorders due to mutations yet to be
identified.
Defective microtubules in mutant SOD1 motor neurons
via stathmin 1 and 2 up-regulation
How does mutant SOD1 induce somatic microtubuli-
nopathy? We show that mutant SOD1 disrupts the cel-
lular microtubule network through up-regulation of the
microtubule-disrupting proteins Stathmin 1 and 2. This
up-regulation is specific to mutant SOD1 since wildtype
SOD1 has no such effect, and it is independent of
SOD1 enzymatic activity since dismutase-inactive SOD1G85R
has a similar effect as dismutase active SOD1G93A.
Interestingly, wildtype and mutant forms of SOD1 have
been localized to the Golgi by biochemical and imaging
methods [63, 64]. We hypothesize that Golgi-localized
mutant SOD1 triggers a Golgi stress response to the nu-
cleus, in analogy to the Golgi-disrupting agents Brefeldin
A and monensin, which activate the signaling cascades
CREB3/ARF4 [45] and TFE3/GASE [59], respectively. Ac-
cording to our bioinformatic analyses, mutant SOD1 does
not modulate the gene expression of the transcription
(See figure on previous page.)
Fig. 5 Stathmin 1/2 overexpression phenocopies expression of mutant SOD1. a. Images showing microtubule alterations in NSC-34 motor neurons
transfected with Myc-tagged Stathmin 1 or Stathmin 2, as compared to control cells. Cells were cultured for 2 DIV, fixed with paraformaldehyde and
analyzed with antibodies α-tubulin (upper panels), detyrosinated tubulin (lower panels) or Myc (not shown). Scale bar 5 μm. b. Quantitative analyses
showing percentage of cells with rarefied or broken microtubules (α-tubulin or detyrosinated tubulin). Data represent one typical out of five independent
experiments each done in quadruplicate per condition. Number of cells analyzed (ctrl, Stathmin 1, Stathmin 2): α-tubulin (175, 174, 139), detyr-tubulin
(184, 146, 152). Statistical significance by Mann–Whitney test: * p < 0.001 as compared to mock. c. Images showing Golgi alterations (MannII-GFP, GS28)
together with microtubule alterations (α-tubulin) in NSC-34 motor neurons transfected with Stathmin 1 or Stathmin 2 as compared to control cells. Scale
bar 5 μm. d. Quantitative analyses showing percentage of cells with Golgi alterations (MannII-GFP) or GS28 dispersal). Data represent one typical out of
five independent experiments each done in quadruplicate per condition. Number of cells analyzed (ctrl, Stathmin 1, Stathmin 2): MannII-GFP (>500 each).
GS28 (482, 434, 526). Statistical significance by Mann–Whitney test: * p < 0.001 as compared to mock. e. Western blot analysis of cells transfected with
plasmids encoding Myc-tagged Stathmin 1 or Stathmin 2 or with an empty control plasmid (pcDNA). GS15 and GS28 levels are increased
after overexpression of Stathmin 1 by 2.7 ± 0.3 and 2.6 ± 0.3 (mean ± sd) respectively. A similar increase in Golgi SNAREs is observed after overexpression of
Stathmin 2 (GS15 2.6 ± 0.2, GS28 2.9 ± 0.3). n = 4 blots corresponding to independent experiments, * p < 0.01 by Mann - Whitney test
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factors CREB3 and TFE3 or their respective effectors
ARF4 and GCP60 (ACBD3), (data not shown). However,
mutant SOD1 enhances gene expression of EZH2 (enhan-
cer of zeste homolog 2), a known de-repressor of the
Stathmin 1 gene [11], by 1.65 fold and 1.56 fold in motor
neurons of two transgenic lines (p = 0.014 and p = 0.003,
dataset GSE46298 [40], providing a potential mechanism
for Stathmin 1 up-regulation. In addition, mutant SOD1
may influence the Stathmin 1 activity through posttransla-
tional modification of its isoforms [55]. These findings
point to a novel Golgi stress response pathway in ALS that
needs to be characterized in further detail.
The respective contribution of Stathmins 1 and 2 to Golgi
fragmentation
Our data show that knockdown of Stathmin 1 or 2 com-
pletely rescues molecular and morphological Golgi alter-
ations. This rules out that Stathmin 1/2 up-regulation is
merely a homeostatic mechanism during Golgi fragmen-
tation, similar to Stathmin up-regulation after axonal in-
jury or during axonal regeneration [25, 32, 49].
We further demonstrate that Stathmin 1 or 2 overexpres-
sion has similar effects on Golgi fragmentation and Golgi
SNARE accumulation in motor neurons. Yet, Stathmins 1
and 2 differ in their subcellular localization in motor neu-
rons (Additional file 1: Figure S4) and in other cell types
[10]. While Stathmin 1 appears mainly cytoplasmic, Stath-
min 2 localizes to the Golgi due to its N-terminal domain
which is missing in Stathmin 1 [9]. This suggests that these
two Stathmins fulfill different functions and potentially act
on distinct microtubule subsets. According to recent studies,
radial centrosomal microtubules are required for the proper
positioning of the Golgi in the cell center whereas microtu-
bules nucleated at the trans-Golgi by CLASPs [14, 34] or at
the cis-Golgi by AKAP450/GM130 [46] seem to be required
for the lateral continuity of Golgi membranes. It can be
speculated that up-regulated Stathmins 1 and 2 coopera-
tively trigger Golgi fragmentation by regulating interdepend-
ent microtubule subsets required for Golgi maintenance.
Are there additional mediators of mutant SOD1-linked
Golgi fragmentation?
Our data indicate that Golgi fragmentation in mutant
SOD1 motor neurons is associated with displacement of
GM130 from intact Golgi membranes to the cytosol
(Fig. 1g). A recent study in mitotic cells shows that GM130
stimulates microtubule polymerization by activating the
microtubule nucleator TPX2 through sequestration of its
inhibitor importin α [67]. Displacement of GM130 to the
cytosol with ensuing TPX2/importin α imbalance may thus
contribute to mutant SOD1-linked microtubule loss and
Golgi fragmentation. Furthermore, mutant SOD1 has
been reported to interact aberrantly with chromogra-
nins [64] and the COPII vesicle subunit Sec23 [4],
which may impede ER-Golgi and Golgi-plasma mem-
brane transport [4, 54, 64] and further enhance Golgi
fragmentation.
Stathmins as potential biomarkers for ALS
Last, this study may contribute to the development of
new disease biomarkers. Biomarkers are generally de-
fined as a physiological process, a pathogenic event or a
pharmacological response to therapeutic intervention
that can be measured. Reliable biomarkers for ALS are
currently lacking [41, 62]. In this respect, Stathmins
display several interesting features.
First, levels of Stathmins 1 and 2 are already significantly
elevated at an early preclinical phase in two lines of mu-
tant SOD1 mice - five months before appearance of clin-
ical symptoms (Fig. 4a-b). Translating this to human ALS
patients would help to establish earlier diagnosis and initi-
ate therapies at a more tractable disease phase.
Second, both Stathmins strongly and continuously ac-
cumulate during disease course in mutant SOD1 G85R
and G93A spinal cords, reaching levels of > 3 fold above
normal at endstage (this study, Fig. 4a-b). To our know-
ledge, this is higher than for any previously reported
protein in ALS spinal cord, and may allow sensitive
monitoring of disease progression.
(See figure on previous page.)
Fig. 6 Stathmin 1/2 knockdown rescues microtubule and Golgi alterations triggered by mutant SOD1. a. Confocal images showing NSC-34 cells
transfected with empty, SOD1wt, SOD1G85R or SOD1G93A plasmids as well as ctrl, Stathmin-1 or Stathmin-2 siRNAs. Cells were immunolabelled for
α-tubulin. Note that knockdown of Stathmin 1 or 2 rescues mutant SOD1-triggered microtubule alterations. Transfected cells were identified by
expression of co-transfected MannII-GFP (not shown). Scale bar 5 μm. b. Diagram showing percentage of microtubule alterations (mean ± sd) under the
different conditions. >150 cells were analyzed per condition. Statistical significance * p < 0.01 by Mann–Whitney test. Data are representative
of three independent experiments. c. Confocal images showing NSC-34 cells transfected as in A and counterstained for GS28. Note rescue
(arrowheads) of mutant SOD1-triggered Golgi fragmentation and GS28 dispersal by knockdown of Stathmin 1 or 2. Scale bar 5 μm. d-e. Diagram showing
percentage (mean ± sd) of Golgi alterations labelled by MannII-GFP (d) or GS28 (e) under the different conditions. >150 cells were analyzed per condition.
Statistical significance * p < 0.01 by Mann–Whitney test. Data are representative of four independent experiments. f-g. Western blots show
efficient siRNA-mediated knockdown (KD) of Stathmin 1 (f) and Stathmin 2 (g) in NSC-34 cells transfected with empty, SOD1wt, SOD1G85R or
SOD1G93A plasmids as compared to ctrl siRNA (upper blots). Both Stathmin-1 or Stathmin-2 knockdown reduces the GS28 up-regulation triggered by
SOD1G85R or SOD1G93A (middle blots). Loading control β-actin (lower blots) indicates reduced protein content in lanes 1 and 2 in F (empty ctrl, empty
Stathmin-1 KD). The diagrams below show densitometric quantification of GS28 protein levels each normalized to β-actin (n = 4 blots, mean ± sd, *
statistically significant differences between ctrl siRNA and Stathmin 1/2 siRNA as measured by Mann - Whitney test)
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Third, Stathmin accumulation represents a patho-
logically relevant feature shared between SOD1-linked
ALS and mutant SMN-linked spinal muscular atrophy
(SMA) [68]. Genetic knockout of Stathmin 1 in Smn mice
improved neuromuscular function presumably through
microtubule stabilization [69], underscoring the pathogenic
relevance of Stathmin 1 up-regulation.
Finally, the proteins Stathmin 1 and 2 are both present
in normal human blood (Plasma Proteome Database [39])
with Stathmin 1 being measured at a plasma concentra-
tion of 3.5 ng/ml [18]. Pathological release of Stathmins
from degenerating ALS motor neurons may thus cause a
detectable increase in their blood levels.
Stathmins and dys-regulated Golgi proteins should
therefore be evaluated as new potential biomarkers for
diagnosis, prognosis or therapy response in ALS, SMA
and related motor neuron disorders.
Conclusions
This study demonstrates that Stathmin 1/2-triggered
microtubule destabilization mediates early presymptom-
atic Golgi fragmentation in mutant SOD1 G85R- and
G93A-triggered ALS. This may contribute to the devel-




Primary and secondary antibodies are listed in Additional
file 1: Table S1. Other reagents were from the following
suppliers: PBS, Hbss, trypsin, culture media and sup-
plements (Invitrogen, Carlsbad, CA), taxol, nocodazole
(Sigma), OCT (Thermo Scientific, Runcorn, UK), Vecta-
shield (Vector laboratories, Burlingame, CA), Complete
protease inhibitors (Roche, Basel, Switzerland), Ketamine
(Bayer, Leverkusen, Germany) and Xylazine (Mérial, Lyon,
France), coverslips and Superfrost Plus glass slides (Menzel,
Schwerte, Germany). Plasmid expression vectors contained
the following cDNAs: GFP-tagged Mannosidase-II (Dr. M.
Bornens, Institut Curie, Paris, France), untagged human
SOD1wt, SOD1G85R or SOD1G93A (Dr. D. Borchelt, Univer-
sity of Florida, Gainesville, USA) subcloned in pCAGGS
vectors, RFP-tagged human SOD1wt, SOD1G85R or
SOD1G93A (Dr. J. Weishaupt, Neurologische Klinik, Ulm,
Germany), Myc-tagged human Stathmin 1 or Stathmin 2
(Dr. A. Sobel, Inserm U693, Paris, France).
Animals
Transgenic SOD1G93A mice (line G1del or
Tg(SOD1*G93Adl)1Gur, http://jaxmice.jax.org/strain/002299.
html [1]), SOD1G85R mice (line 148 [6] and SOD1wt mice
(line 76 [6]) were maintained as hemizygotes for more
than ten generations on a C57/BL6 background and ge-
notyped by PCR as described [44]. All experiments with
animals were performed in strict compliance with
French and European legislation.
Cell culture
NSC-34 cells [7] were cultured in DMEM supplemented
with 8 % (v/v) fetal calf serum at 37 °C and 7.5 %
CO2and differentiated on collagen-coated wells in low
fetal calf serum (1 %) for 72 h before transfection. Cells
were transfected with plasmids encoding SOD1 (mutant
or wildtype, RFP-tagged or not), RFP, Stathmin-1 or
Stathmin-2 (0.2 μg/104 cells) and/or with siRNAs
against Stathmin 1/2 (on target plus, Thermofisher) or
luciferase control (Thermofisher) using Lipofectamine
2000 (Invitrogen) as described [48]. Cells were then
cultured for 96 h after SOD1 plasmid and/or Stathmin
siRNA transfection or for 48 h after Stathmin plasmid
transfection.
Immunocytochemistry
Mice deeply anaesthetized with ketamine/xylazine were
intracardially perfused with Sorensen buffer followed by
4 % paraformaldehyde. Spinal cords were dissected out,
postfixed, cryoprotected in sucrose and frozen in OCT.
Cross sections (30 μm) of lumbar spinal cord were cut
with a crytotome (Leica) and stained with antibodies as
described [5].
Cultured cells were fixed in 4 % formaldehyde (FA),
permeabilized with 0.5 % (v/v) Tween in PBS and
blocked in a solution containing 2.5 % (v/v) goat serum,
2.5 % (v/v) donkey serum, 1 % (w/v) BSA in PBS. Alter-
natively, cells were extracted for soluble proteins using
MSB (25 mM Hepes, 50 mM Pipes, 10 mM EGTA,
2 mM MgCl2, 1 % formaldehyde in PBS pH 7.0), perme-
abilized in MSB containing 10 μM Taxol and 0.2 % (v/v)
Triton X100 and fixed with 4 % formaldehyde. Cells
were stained with antibodies as described [5].
Confocal imaging, morphometry and 3D modeling
Motor neurons in ventral spinal cord were identified by
expression of vesicular acetyltransferase (VAChT) or cho-
line acetyltransferase (ChAT), large soma size and faintly
DAPI-stained large nucleus [5]. Motor neurons were im-
aged with an LSM 510 confocal microscope (Zeiss, Ober-
kochen, Germany) using a 63x objective, an xy-resolution
of 1024 x 1024 pixel and a z-interval of 0.3 μm.
Morphometric analyses were done with Metamorph soft-
ware (Molecular Dynamics) using single confocal cross sec-
tions taken at the nuclear midplane. The boundaries of the
VAChT-labelled cell soma and the DAPI-stained nucleus
were manually delineated with the Metamorph drawing tool.
Golgi area was automatically determined with the Meta-
morph morphometry tool by applying a fixed threshold to
the GM130 signal. Three-dimensional (3D) modelings of the
Golgi apparatus were done with Imaris software (Bitplane,
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Zurich, Switzerland). Images were processed and Golgi
membranes visualized using the IsoSurface mode of the
Surpass module. The number of individual Golgi elements
per motor neuron was determined in a blinded manner.
NSC-34 cells were imaged by confocal microscopy using a
z-interval of 0.3 μm and a scan depth of about 10 μm.
The percentage of spinal cord motor neurons display-
ing Golgi fragmentation (labelled by GM130 or MG160)
was determined by conventional microscopy using a Leica
DMI 400 fluorescence microscope (63x oil objective).
Golgi fragmentation in lumbar spinal cord motor neurons
was defined by discontinuous or decreased GM130 or
MG160 immunolabeling.
The percentage of transfected NSC-34 cells with sub-
cellular alterations was also quantified by fluorescence
microscopy. Golgi dispersal was defined by enlarged
area, as compared to neighboring non-transfected cells.
A defective microtubule network was defined by less dense
or discontinuous microtubules labeled for α-tubulin or
detyrosinated tubulin, as compared to neighboring
non-transfected cells.
Electron microscopy
Deeply anaesthetized mice were transcardially perfused
with Sorensen’s phosphate buffer (pH 7.4) followed by
glutaraldehyde (2 % v/v in cacodylate). Spinal cords were
dissected out, postfixed for 24 h and cut into small seg-
ments comprising the ventral spinal cord before pro-
cessing for resin embedding (epon) following standard
protocols. 60 nm ultrathin cross sections were contrasted
with uranyl acetate and visualized under a JEOL electron
microscope. Two sections each containing up to 30 motor
neurons were analyzed per mouse line. Motor neurons
were recognized on the basis of their frequency (1:20),
large size and pale nucleus with nucleolus.
Immunoblots and subcellular fractionation
Protein extracts from lumbar spinal cords or NSC-34
cells were prepared by homogenization in lysis buffer con-
taining 50 mM Tris HCl pH7.5, 150 mM NaCl, 2 mM
EDTA, 1 % Triton X100, protease inhibitors (Complete
EDTA-free, Roche). 50 μg protein were subjected to SDS-
PAGE and blotted on Immobilon membranes (Millipore)
which were processed by standard methods and revealed
with Immobilon Western kits (Millipore). Band intensities
were quantified by TotalLabQuant software.
Crude fractionation of membranes from lumbar spinal
cord was performed after tissue freezing (−80 °C), thawing
and homogenization in 50 mM HEPES, pH 7.4, 250 mM
sucrose, 1 mM Mg-acetate and protease inhibitors
(Complete EDTA-free, Roche). Lysates were homogenized
using a Dounce homogenizer (15 passes) and centrifuged at
1.000 g for 10 min. The postnuclear supernatant was cen-
trifuged at 10.000 g for 30 min at 4 °C yielding a P10 pellet
and the supernatant was centrifuged at 100.000 g (Beckman
TLA-110) for 1 h at 4 °C yielding an S100 supernatant and
a P100 pellet.
Tubulin and microtubule assays
Tubulin polymerization status in NSC-34 cells was
analyzed by preparing cell lysates in microtubule
stabilization buffer (MSB, 0.1 M PIPES pH 6.75, 1 mM
EGTA, 1 mM MgSO4, 30 % glycerol, 5 mM GTP, 5 %
DMSO, 1 mM DTT, MiniComplete protease inhibitors).
Total tubulin (T) was harvested before fractionation and
soluble tubulin (supernatant, S) and precipitable tubulin
(pellet, P) were separated by centrifugation for 1 h at 100
000 g in a Beckman Rotor TLA-100.
Cellular microtubule content was determined by flow
cytometry using the method of Morrison et al. [35] with
some modifications. Briefly, cells were harvested, rinsed
with PBS, centrifuged, washed with MSB and treated for
3 min with MSB containing 0.1 % Triton X-100 and
20 μM taxol. Cells were then fixed in formaldehyde,
centrifuged, washed, blocked, incubated for 1 h with
FITC-coupled antibodies against α-tubulin and washed.
1500 RFP-positive cells per duplicate sample and condi-
tion were analyzed with a FACS ARIA SORP cytometer
(Becton Dickinson) and FITC signals plotted with FlowJo
software. Control experiments with cells that had been
treated with Nocodazole or Taxol showed accuracy.
Growth dynamics of Golgi-derived microtubule were
determined essentially as described [5]. Briefly, cells co-
transfected with MannII-GFP and RFP or RFP-SOD1 plas-
mids were treated with nocodazole at 5 DIV (10 μM, 5 h,
37 °C). Nocodazole was then washed out, cultures further
incubated for up to 12 min, fixed as indicated above, blocked
and counterstained for α-tubulin. After confocal imaging of
entire cells, length of Golgi-derived microtubules was deter-
mined using Metamorph and ImageJ software respectively.
Data mining and bioinformatics
Datasets from [19] and [40] were downloaded from the
Gene Omnibus database (GSE10953 and GSE46298
respectively). Analysis and visualization of the correspond-
ing Affymetrix CEL files were made using EASANA®
software (GenoSplice technology), which is based on the
GenoSplice’s FAST DB® annotations [13]. Briefly, micro-
array data were normalized using RMA and genes were
considered significantly differentially expressed when the
uncorrected p-value from unpaired Student’s t-test was
lower or equal to 0.05 and fold-change greater or equal to
1.5. Significant KEGG pathways and Gene Ontology terms
were retrieved using DAVID.
Statistical analyses
Each experiment was performed with several biological
replicates (see Figure Legends) and repeated at least
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twice. Data were analysed with Microsoft Excel or Graph-
Pad Prism (GraphPad). Data from two groups showing
each Gaussian distribution were analysed with student's
t-test; otherwise the Mann–Whitney U test was used.
Data from more than two groups showing each Gaussian
distribution and equal variance were analyzed with
One Way ANOVA and Tukey posthoc test; otherwise
Kruskal-Willis test and Dunn posthoc test were used.
Cytometry data were tested for significance with the
Chi square test using FlowJo software. Immunofluores-
cence data were tested for Gaussian distribution by
D’Agostino & Pearson test and linear regression and cor-
relation quantified with GraphPad Prism. Subcellular co-
localization of SOD1 and MannII-GFP was correlated by
computing Pearson coefficients with the image processing
package Fiji using six independents assays.
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analysis of cellular microtubules. Figure S4. Labeling of spinal cord
sections from SOD1 G85R mice with antibodies against Choline
Acetyltransferase (ChAT), Stathmins 1 or 2, Golgi SNARE GS28 and DAPI
(nuclei). Figure S5. Subcellular localization of Stathmins. (PDF 10467 kb)
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